Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases.
Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases.
复制标题
DOI：
10.7314/apjcp.2015.16.7.2685
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Yangchun Zhou;Haijian Zhao;Linda Shen
中科院分区：
文献类型：
--
作者：
Yangchun Zhou;Haijian Zhao;Linda Shen
为评价术前血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)对可切除胃癌(GC)的临床意义，回顾分析2012年1月至2013年12月某三级医院连续1075例胃腺癌患者血清CEA、CA19-9水平与临床病理特征的关系。术前血清CEA和CA19-9阳性率分别为22.4%和12.3%，两者水平与肿瘤侵袭深度、淋巴结转移、pTNM和分期显著相关。CEA水平也与淋巴血管侵犯显著相关。CEA和CA19-9阳性表达与肿瘤侵袭深度、淋巴结转移、pTNM分期、淋巴管侵犯、肿瘤大小、肿瘤部位呈显著正相关。按性别或肿瘤部位分层分析显示，CEA或CA19-9与不同性别或部位亚组的临床病理特征有不同的相关性。术前血清CA19-9阳性对肿瘤大小可能比CEA更有意义。综上所述，术前血清CEA和CA19-9水平与胃癌的病情进展密切相关，有助于更准确地判断肿瘤的分期、治疗方案的选择和预后评估。
To evaluate the clinical impact of preoperative serum CEA and CA19-9 on resectable gastric cancer (GC), a total of 1,075 consecutive cases with gastric adenocarcinoma were obtained retrospectively from January 2012 and December 2013 in a single tertiary hospital, and the relationships between serum CEA, CA19-9 and clinicopathologic features were investigated. Positive preoperative serum rates of CEA and CA19-9 were 22.4% and 12.3% respectively, levels significantly correlating with each other and depth of invasion, lymph node involvement, pTNM and stage. The CEA level also presented a remarkable association with lymphovascular invasion. Both CEA and CA19-9 positivity significantly and positively correlated with depth of invasion, nodal involvement, pTNM stage, lymphovascular invasion, tumor size and tumor location. Stratified analyses according to gender or tumor location showed preoperative CEA or CA19-9 had different associations with clinicopathologic features in different gender subgroups or location subgroups. Preoperative serum CA19-9 positivity may be more meaningful for tumor size rather than CEA. In conclusion, preoperative serum CEA and CA19-9 correlate with disease progression of GC, and may have applications in aiding more accurate estimation of tumor stage, decision of treatment choice and prognosis evaluation.